PharmaTelevision - Syntaxin: Melanie Lee explains their biological platform, based on Botulinum Toxin, and its primary indications

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Syntaxin: Melanie Lee explains their biological platform, based on Botulinum Toxin, and its primary indications

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Melanie Lee, CEO of Syntaxin

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Syntaxin: Origin and fundings

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Oxford. On this show I have Melanie Lee, who is CEO of a company called Syntaxin which is based here in Oxford, welcome.

Melanie Lee:

Thank you.

Fintan Walton:

Melanie, you are a now CEO of a company called Syntaxin as I mentioned and your own background has been at GSK and you've spent a number of years quite important years at Celltech, UCB Celltech now UCB I suppose, could you tell us first of all little bit about Syntaxin's origin and what is it about Syntaxin that makes you want to join it?

Melanie Lee:

Yes, I was a consultant for Syntaxin after I left UCB and why I joined it was because I saw a platform in Syntaxin the like of which I haven't seen in reviewing many other companies and Syntaxin's platform is based from a technology that came from Porton Down where the Health Protection Agency spun them out in 2005.

Fintan Walton:

Okay, so we will come on to the some details on technology obviously one of the key questions is are you funded and how well funded are you?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Melanie Lee

CEO

Melanie Lee Melanie Lee currently is CEO of Syntaxin. Dr Lee was formerly President of New Medicines and Executive Vice President R&D with UCB, having served as R&D Director at Celltech before its merger with UCB. Dr Lee brings a wealth of drug research and development experience to Syntaxin, through her early academic career at Cancer Research UK (as ICRF), a decade in research with GlaxoSmithKline and her later leadership of biopharmaceutical R&D at Celltech and UCB. Dr Lee currently Chairs Cancer Research Technology, an early drug R&D and technology licensing company of CRUK.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Syntaxin

Syntaxin has a strong and unique biologics platform that delivers a pipeline of Targeted Secretion Inhibitors (TSI). The platform has the potential to generate multiple products to treat diseases where secretion is the major driver. These are large market opportunities, such as the treatment of pain , endocrine conditions and cancer . Syntaxin was founded in late 2005 through a spinout of intellectual property and scientists from the Health Protection Agency, and benefits from 15 years of research in the field of bacterial toxin engineering. The company owns dominant patents and know how in the design, manufacture and use of novel cell TSI based on engineered botulinum toxins. It has established a strong IP base with over 40 granted patents covering the platform and products. It is backed by a blue chip investor base including: Abingworth, Lundbeck Ventures, LSP, up Ipsen, JJDC, Quest , Seventure, and SR One.